Cancer Supportive Care Medicine Market is Anticipated to Increase at a Stable CAGR over the Forecast Period (2023 to 2029)

Cancer supportive care medicine market is anticipated to grow at a significant CAGR during the forecast period. Cancer supportive care medicines are the kinds of drugs that are used to alleviate the harmful side effects caused by cancer treatment through protecting certain cells or organs. Among these treatment methods, chemotherapy is broadly known to cause side effects such as loss of appetite, severe nausea and vomiting, among others. Thus, the rising prevalence of cancer is acting as the pivotal factors responsible for the increased demand for these medicines. Adding to this, the global cancer supportive care medicine market is also driven by extensive R&D along with the new FDA approvals. For instance, in April 2021, Caplin Steriles has been granted final approval from the US FDA for its abbreviated new drug application (ANDA) prochlorperazine edisylate injection USP, 10 mg/2 mL (5 mg/mL) vials. Prochlorperazine edisylate injection is an antiemetic drug that is indicated for the control of severe nausea and vomiting.

Some key players operating in the market include Amgen Inc., Novartis International AG, and Merck & Co., Inc., among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in November 2021, Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the US Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion. HTX-019 injectable emulsion is intended to be used for the prevention of postoperative nausea and vomiting (PONV) in adults.

To Request a Sample of our Report on Cancer Supportive Care Medicine Market: https://www.omrglobal.com/request-sample/cancer-supportive-care-medicine-market

Market Coverage

• The market number available for - 2022-2030

• Base year- 2022

• Forecast period- 2023-2030

Segment Covered-

· By Drug Class

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: Amgen Inc., Novartis International AG, and Merck & Co., Inc., among others.

Cancer Supportive Care Medicine Market Report by Segment

By Drug Class

• G-CSFs (Granulocyte Colony-Stimulating Factor)

• ESAs (Erythropoiesis Stimulating Agent)

• Antiemetics

• Bisphosphonates

• Opioids

• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

• Topical

• Others

A full Report of Cancer Supportive Care Medicine Market is Available @ https://www.omrglobal.com/industry-reports/cancer-supportive-care-medicine-market

Cancer Supportive Care Medicine Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.